Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, 06 1997, 1359-1363, Vol 41, No. 6
MJ Rybak, HH Houlihan, RC Mercier and GW Kaatz
We evaluated the bactericidal activity of RP 59500 (quinupristin-
dalfopristin) against fibrin-platelet clots (FPC) infected with two
clinical isolates of Staphylococcus aureus, one constitutively erythromycin
and methicillin resistant (S. aureus AW7) and one erythromycin and
methicillin susceptible (S. aureus 1199), in an in vitro pharmacodynamic
infection model. RP 59500 was administered by continuous infusion (peak
steady-state concentration of 6 microg/ml) or intermittent infusion
(simulated regimens of 7.5 mg/kg of body weight every 6 h (q6h) q8h, and
q12h. FPCs were infected with S. aureus to achieve an initial bacterial
density of 10(9) CFU/g. Model experiments were run in duplicate over 72 h.
Two FPCs were removed from each model at 0, 12, 24, 36, 48, and 72 h, and
the bacterial densities (in CFU per gram) were determined and compared to
those of growth control experiments. Additional samples were also removed
from the model over the 72-h period for pharmacokinetic evaluation. All
regimens significantly (P < or = 0.01) decreased bacterial densities in
the infected FPCs for both isolates compared to growth controls. This
occurred even though MBCs were equal to or greater than the RP 59500
concentrations achieved in the models. There were no significant
differences found between the dosing frequencies and levels of killing when
examining each isolate separately. However, examination of the residual
bacterial densities (CFU per gram at 72 h) and visual inspection of the
overall killing effect (killing curve plots over 72 h) clearly demonstrated
a more favorable bactericidal activity against 1199 than against the AW7
isolate. This was most apparent when the q8h and the q12h AW7 regimens were
compared to all 1199 treatment regimens by measuring the 72-h bacterial
densities (P < or = 0.01). Killing (99.9%) was not achieved against the
AW7 isolate. However, a 99.9% kill was demonstrated for all dosing regimens
against the 1199 isolate. The area under the concentration-time curve from
0 to 24 h was found to be significantly correlated with reduction in
bacterial density for the AW7 isolate (r = 0.74, P = 0.04). No resistance
was detected during any experiment for either isolate. RP 59500 efficacy
against constitutively erythromycin- and methicillin-resistant S. aureus
may be improved by increasing organism exposure to RP 59500 as a function
of dosing frequency.
Copyright © 1997 by the American Society for Microbiology. All rights reserved.
Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model
Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, Wayne State University, Michigan 48201, USA. mrybak@cms.cc.wayne.edu
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»